Skip to main content
Log in

Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Tamoxifen, an antiestrogen used in the treatment of breast cancer, was assessed for carcinogenic potential in the two-stage model of experimental hepatocarcinogenesis. Groups of female Fischer F344 rats were initiated with a non-necrogenic, subcarcinogenic dose of diethylnitrosamine (DEN; 10 mg/kg, po) and fed tamoxifen at a concentration of 250 mg per kg of AIN-76A diet for 6 or 15 months. The livers of these animals exhibited an increase in size and number of altered hepatic foci compared with those animals which were initiated with DEN but not exposed to tamoxifen. This finding indicates that tamoxifen may have a carcinogenic potential in the rat liver. After 6 months of treatment, neoplastic nodules were observed in 3/8 rats in the DEN-initiated, tamoxifen-treated group. In the initiated group provided with tamoxifen for 15 months, neoplastic nodules were observed in 7/8 rats and hepatocellular carcinomas in 3/8 rats. The serum level of tamoxifen in these rats was 200–300 ng/ml. The ratio of tamoxifen, 4-hydroxy tamoxifen, and N-desmethyl tamoxifen was 1:0.1:0.5-1 in the serum. When adjusted for age-related weight increases, the serum and liver levels of tamoxifen and its N-desmethyl metabolite did not change over the 15 months. In the rat liver, the level of tamoxifen and its N-desmethyl metabolite was 10-29 µg/g liver after 6 or 15 months of chronic dietary administration. The ratio of tamoxifen:4-hydroxy tamoxifen:N-desmethyl tamoxifen was 1:0.1:1.3-2.3 in the liver. Therefore, the liver had 20- to 30-fold more tamoxifen and 4-hydroxy tamoxifen and at least 100-fold more N-desmethyl tamoxifen than the serum (assuming 1 gram of tissue is equivalent to 1 ml of serum). These results indicate that tamoxifen is a promoting agent for the rat liver at serum levels found in patients given the usual therapeutic course of tamoxifen. The high concentrations of tamoxifen attained in the rat liver indicate that actions other than its known estrogenicity for liver could contribute to its promoting action. In addition, these results indicate that the pharmacodynamic differences in tamoxifen metabolism in rats and humans and at low versus high doses should be determined. Thus, the therapeutic indications for tamoxifen should be balanced by the potential risk it may present as a promoting agent in mammalian liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buchanan R, Blamey R, Durrant K, Howell A, Paterson A, Preese P, Smith D, Williams C, Wilson R: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326–1330, 1986

    Google Scholar 

  2. Cole M, Jones C, Todd I: A new antiestrogenic agent in late breast cancer: an early clinical appraisal of ICI 46,474. Br J Cancer 25: 270–275, 1971

    Google Scholar 

  3. Ingle J, Krook J, Green S, Kubista, Everson L, Ahmann D, Chang M, Bisel H, Windschitl H, Twito D, Pfeifle D: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185, 1986

    Google Scholar 

  4. Manni A, Pearson O: Anti-oestrogen-induced remissions in premenopausal women with Stage IV breast cancer: effects on ovarian culture. Cancer Treat Rep 64: 779–785, 1980

    Google Scholar 

  5. Sawka C, Pritchard K, Paterson D, Sutherland D: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res 46: 3152–3156, 1986

    Google Scholar 

  6. Tormey DC, Simon R, Lippman M, Bull J, Myers C: Evaluation of tamoxifen in advanced breast cancer: a progress report. Cancer Treat Rep 60: 1451–1459, 1976

    Google Scholar 

  7. Ward HWC: Antiestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J i: 13–14, 1973

    Google Scholar 

  8. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocrin Rev 11: 578–610, 1990

    Google Scholar 

  9. Jordan VC: Long-term tamoxifen therapy for breast cancer. In: DeVita VT, Hellman S, Rosenberg S (eds) Important Advances in Oncology. Lippincott, Philadelphia, 1989, pp 179–192

    Google Scholar 

  10. Early Breast Trials Cooperative Group: Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319: 1681–1692, 1988

    Google Scholar 

  11. Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297–302, 1984

    Google Scholar 

  12. Delozier T, Julien J, Juret P, Veyret C, Couette J-E, Graic Y, Ollivier J-M, de Ranieri E: Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res Treat 7: 105–110, 1986

    Google Scholar 

  13. Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, Dimitrov N, Legault-Poisson S, Schipper H, Prager D: Prolonging tamoxifen therapy for primary breast cancer. Ann Intern Med 106: 649–654, 1987

    Google Scholar 

  14. Falkson H, Gray R, Wolberg W, Gilchrist K, Harris J, Tormey D, Falkson G: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol 8: 599–607, 1990

    Google Scholar 

  15. Diver JMJ, Jackson IM, Fitzgerald JD: Tamoxifen and nonmalignant indications. Lancet i: 733, 1986

    Google Scholar 

  16. Fentiman IS, Powles TJ: Tamoxifen and benign breast problems. Lancet ii: 1070–1072, 1987

    Google Scholar 

  17. Prentice R: Tamoxifen as a potential preventative agent in healthy postmenopausal women. J Natl Cancer Inst 82: 12–13, 1990

    Google Scholar 

  18. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Coutre J, Dimitrov N, Wolmark N, Wickerham DL, Fisher E, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman M, Farrar W, Evans J, Lickley HL, Ketner Met al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 320: 479–484, 1989

    Google Scholar 

  19. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, Rutquist LE, Silfversward C, Somell A, Wilking N, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet i: 117–120, 1989

    Google Scholar 

  20. Nayfield S, Karp J, Ford L, Dorr F, Kramer B: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83: 1450–1459, 1991

    Google Scholar 

  21. Powles T, Tillyer C, Jones A, Ashley S, Treleaven J, Davey J, McKinna J: Prevention of breast cancer with tamoxifen -an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26: 680–684, 1990

    Google Scholar 

  22. Jordan VC: Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials. In: Hankins WD, Puett D (eds) Hormones, Cell Biology, and Cancer: Perspectives and Potentials. AR Liss Inc., New York, 1988, pp 105–123

    Google Scholar 

  23. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Therap Pharm 25: 127–205, 1984

    Google Scholar 

  24. Jordan VC, Allen KE, Dix CJ: Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64(6-7): 745–759, 1980

    Google Scholar 

  25. Jordan VC: The pharmacology of antiestrogens. In: Rose DP (ed) CRC-Endocrinology of Cancer 3. CRC Press, Boco Raton FL, 1982, pp 129–179

    Google Scholar 

  26. Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C, Moore J, Parsons V, Pemberton K, Pitt P, Richmond W, Houghton J, Riley D: Long term effects of tamoxifen. Biological effects of tamoxifen working group. Europ J Cancer 29A: 15–21, 1993

    Google Scholar 

  27. Helgason S, Wilking N, Carlstron K, Damber M-G, von Schoultz B: A comparative study of the estrogenic effects of tamoxifen and 17β estradiol in postmenopausal women. J Clin Endocrin Metab 54: 404–408, 1982

    Google Scholar 

  28. Jordan VC: Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat 15: 125–136, 1990

    Google Scholar 

  29. Love R, Newcomb P, Wiebe D, Surawicz T, Jordan V, Carbone P, DeMets D: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative disease. J Natl Cancer Inst 82: 1327–1332, 1990.

    Google Scholar 

  30. Fornander T, Rutqvist L, Sjoberg, H, Blomqvist L, Mattison A, Glas U: Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8: 1019–1024, 1990

    Google Scholar 

  31. Gusberg SB: Tamoxifen for breast cancer: associated endometrial cancer. Cancer 65: 1463–1464, 1990

    Google Scholar 

  32. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic nude mouse. Cancer Res 48: 812–815, 1988

    Google Scholar 

  33. Tamoxifen for node negative breast cancer. FDA Drug Bulletin 20: 5, 1990

  34. Hirsamaki P, Hirsamaki Y, Nieminen L, Payne BJ: Tamoxifen induces hepatocellular carcinoma in rat liver: a one year study with two antiestrogens. Arch Toxicol 67: 49–54, 1993

    Google Scholar 

  35. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP: The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14: 315–317, 1993

    Google Scholar 

  36. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T: Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919–3924, 1993

    Google Scholar 

  37. Gau TC: Open letter concerning Nolvadex. Stuart Pharmaceuticals, 1987

  38. Sasco A: Tamoxifen: a carcinogen as a preventive agent. Cancer J 4: 217–218, 1991

    Google Scholar 

  39. Davidson N: Tamoxifen - panacea or Pandora's box? N Engl J Med 326: 885–886, 1992

    Google Scholar 

  40. Williams G, Iatropoulos M, Hard G: Long-term prophylactic use of tamoxifen: is it safe? Europ J Cancer Prev 1: 386–387, 1992

    Google Scholar 

  41. Fugh-Berman A, Epstein S: Should healthy women take tamoxifen? N Engl J Med 22: 1596, 1992

    Google Scholar 

  42. Mishkin SY, Farber E, Ho RK, Mulay S, Mishkin S: Evidence for the hormone dependency of hepatic hyperplastic nodules: inhibition dependency of malignant transformation after endogenous 17β estradiol and tamoxifen. Hepatology 3: 308–316, 1983

    Google Scholar 

  43. Kohigashi K, Fukuda Y, Imura H: Inhibitory effect of tamoxifen on DES-promoted hepatic tumorigenesis in male rats and its possible mechanism of action. Gann 79: 1335–1339, 1988

    Google Scholar 

  44. Taper HS: The effect of estradiol-17-phenylpropionate and estradiol benzoate on N-nitrosomorpholine-induced liver carcinogenesis in ovariectomized female rats. Cancer 42: 462–467, 1978

    Google Scholar 

  45. Yager JD, Yager R: Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 40: 3680–3685, 1980

    Google Scholar 

  46. Wanless IR, Medline A: Role of estrogens as promoters of hepatic neoplasia. Lab Invest 46(3): 313–320, 1982

    Google Scholar 

  47. Edmonson HA, Reynolds TB, Henderson B: Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 86: 180–182, 1977

    Google Scholar 

  48. Kneiffel MA, Katzenellenbogen BS: Comparative effects of estrogen and antiestrogens on plasma renin substrate levels and hepatic estrogen receptors in the rat. Endocrinology 108: 595–652, 1981

    Google Scholar 

  49. Kendall ME, Rose DP: The effects of diethylstilbesterol, tamoxifen, and toremifene on estrogen inducible hepatic protein and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127–131, 1992

    Google Scholar 

  50. Sakai F, Cheix F, Clavel M, Colon J, Mayer M, Pannata E, Saez S: Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrin 76: 219–226, 1978

    Google Scholar 

  51. Szamel I, Vincze B, Hindy I, Hermann I, Borvendeg J, Eckhardt S: Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer. Oncology 43: 7–11, 1986

    Google Scholar 

  52. Popper H, Selikoff IJ, Maltoni C, Squire RA, Thomas LB: Comparison of neoplastic hepatic lesions in man and experimental animals. In: Hiatt HH, Watson JD, Winsten JA (eds) Origins of Human Cancer Book C. Human Risk Assessment. Cold Spring Harbor Laboratory, New York, 1977, 1359–1382

    Google Scholar 

  53. Pitot HC: Principles of carcinogenesis: chemical. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer-Principles and Practice of Oncology. Vol 1, 3rd edition, JB Lippincott Co, Philadelphia, 1989, pp 116–135

    Google Scholar 

  54. Pitot HC, Barsness L, Goldsworthy T, Kitagawa T: Biochemical characterization of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature (Lond) 271: 456–458, 1978

    Google Scholar 

  55. Goldsworthy T, Pitot HC: An approach to the development of a short-term whole animal bioassay to distinguish initiating (incomplete) carcinogens, complete carcinogens, and noncarcinogens in the rat liver. - J Toxic Environ Health 16: 389–402, 1986

    Google Scholar 

  56. Scherer E, Emmelott P: Kinetics of induction and growth of precancerous liver-cell foci, and liver tumor formation by DEN in rats. Europ J Cancer 11: 689–696, 1975

    Google Scholar 

  57. Peraino C, Staffeldt E, Carnes B, Vessilinovitch S: Characterization of histochemically detectable altered hepatic foci and their relationship to hepatic tumorigenesis in rats treated once with DEN or B(a)P within one day of birth. Cancer Res 44: 3340–3347, 1984

    Google Scholar 

  58. Hendrich S, Campbell HA, Pitot HC: Quantitative stereological evaluation of four histological markers of altered foci in multistage hepatocarcinogenesis in the rat. Carcinogenesis 8: 1245–1250, 1987

    Google Scholar 

  59. Campbell HA, Pitot HC, PotterVR, Laishes BA: Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res 42: 465–472, 1982

    Google Scholar 

  60. Campbell HA, Xu YD, Hanigan MH, Pitot HC: Application of quantitative stereology to the evaluation of phenotypically heterogeneous enzyme-altered foci in the rat liver. J Natl Cancer Inst 76: 751–767, 1982

    Google Scholar 

  61. Squire RA, Levitt: Workshop on classification of specific hepatocellular lesions in the rat. Cancer Res 35: 3214–3223, 1975

    Google Scholar 

  62. Hsu S, Raine L, Fanger H: A comparative study of the peroxidase-antiperoxidase method and an avidin biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75: 734–738, 1981

    Google Scholar 

  63. Bondi A, Chieregatti G, Eusabi V, Fulcheri E, Bussolatti G: The use of β-galactosidase as a tracer in immunocytochemistry. Histochemistry 76: 153–158, 1982

    Google Scholar 

  64. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19: 36–43, 1991

    Google Scholar 

  65. Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Europ J Cancer 26: 883–888, 1990

    Google Scholar 

  66. Brown RR, Bain RR, Jordan VC: Determination of tamoxifen and metabolites in human serum by high pressure liquid chromatography with post column fluorescence activation. J Chromat 272: 351–358, 1983

    Google Scholar 

  67. Etienne M, Milano G, Fischel J, Frenay M, Francois E, Formento J, Gioanni J, Namer M: Tamoxifen metabolism: pharmacokinetic andin vitro study. Br J Cancer 60: 30–35, 1989

    Google Scholar 

  68. Lien E, Solheim E, Ueland P: Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Res 51: 4837–4844, 1991

    Google Scholar 

  69. Bratherton D, Brown C, Buchanan R, Hall V, Pillers E, Wheeler T, Williams C: A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50: 199–205, 1984

    Google Scholar 

  70. Watanabe M, Tanaka H, Koizumi H, Tanimoto Y, Torii R, Yanagita T: General toxicity studies of tamoxifen in mice and rats. Jitchuken Zenrinsko Kenkyuko 6: 1–36, 1980

    Google Scholar 

  71. Harper MJK, Walpole AL: Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 21: 87, 1966

    Google Scholar 

  72. Dragan YP, Sargent L, Xu YD, Xu YH, Pitot HC: The initiation-promotion-progression model of rat hepatocarcinogenesis. Proc Soc Exp Biol Med 202: 16–24, 1993

    Google Scholar 

  73. Pitot HC, Goldsworthy TL, Moran S, Keenan W, Glauert HP, Maronpot RR, Campbell HA: A method to quantitate the relative initiating and promoting potencies of hepatocarcinogenic agents in their dose-response relationships to altered hepatic foci. Carcinogenesis 8: 1491–1499, 1987

    Google Scholar 

  74. Metzler M, Schiffmann D: Structural requirements for thein vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene type antiestrogens. Am J Clinical Oncol 14: S30-S35, 1991

    Google Scholar 

  75. Han X, Liehr J: Induction of covalent adducts in rodents by tamoxifen. Cancer Res 52: 1360–1363, 1992

    Google Scholar 

  76. Mani C, Kupfer D: Cytochrome P450 mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver; possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 51: 6052–6058, 1991

    Google Scholar 

  77. White INH, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH: Genotoxic potential of tamoxifen and analogues in female Fischer F244/n rats, DBA/2 and C57BL/6 mice, and human MCL-5 cells. Carcinogenesis 13: 2197–2203, 1992

    Google Scholar 

  78. Tucker MJ, Adam HK, Patterson JS: Tamoxifen. In: Laurence DR, McLean AEM, Wetherall (eds) Safety Testing of New Drugs. Laboratory Predictions and Clinical Performance. Academic Press, London, 1984, pp 125–161

    Google Scholar 

  79. Maltoni C, Pinto C, Paladini G: Project of experimental bioassays on chemoprevention agents performed at the Bologna Institute of Oncology: Report on tamoxifen control of spontaneous mammary tumors in Sprague-Dawley rats. Cancer Invest 6: 643–658, 1988

    Google Scholar 

  80. Hirsimaki P, Hirsamaki Y, Nieminen L: The effects of tamoxifen citrate and toremifene citrate on the ultrastructure of the rat liver. Inst Phys Conf Ser 93: 235–236, 1988

    Google Scholar 

  81. Yager JD, Roebuck BD, Paluscyk TL, Memoli VA: Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase positive foci in female rats. Carcinogenesis 7: 2007–2014, 1986

    Google Scholar 

  82. Ghia M, Mereto E: Induction and promotion of γglutamyltranspeptidase-positive foci in the livers of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. Cancer Lett 46: 195–202, 1989

    Google Scholar 

  83. Dragan YP, Xu YH, Pitot HC: Tumor promotion as a target of estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prevent Med 20: 15–26, 1991

    Google Scholar 

  84. Dragan YP, Rizvi TA, Xu YH, Hully JR, Maronpot RR, Campbell HA, Pitot HC: An initiation-promotion assay in rat liver as a potential complement to the two-year bioassay. Fund Appl Toxicol 16: 525–547, 1991

    Google Scholar 

  85. Board of Scientific Advisors: Report of the NTP Ad Hoc Panel on chemical carcinogenesis testing and evaluation. NTP 248-254; 264-266, 1984

    Google Scholar 

  86. Lüllmann H, Lüllmann-Rauch R: Tamoxifen-induced generalized lipidosis in rats subchronically treated with high doses. Toxicol Appl Pharmacol 61: 138–146, 1981

    Google Scholar 

  87. Hendrich S, Glauert H, Pitot H: Dietary effects on initiation and promotion of hepatocarcinogenesis in the rat. J Cancer Res Clin Oncol 114: 49–157, 1988

    Google Scholar 

  88. Hendrich S, Glauert H, Pitot H: A semipurified diet that suppresses phenobarbital promotion of hepatocarcinogenesis in the rat. Nutr Cancer 12: 249–258, 1988

    Google Scholar 

  89. Juedes M, Kupfer D: The role of P450c in the formation of a reactive intermediate of chlorotrianisene (TACE) by hepatic microsomes from methylcholanthrene treated rats. Drug Metabol Dispos 18: 131–137, 1990

    Google Scholar 

  90. Juedes M, Bulger W, Kupfer D: Monooxygenase mediated activation of chlorotrianisene (TACE) in covalent binding to rat hepatic microsomal protein. Drug Metabol Dispos 15: 786–793, 1987

    Google Scholar 

  91. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F: Identification of the cytochrome IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41: 1911–1919, 1991

    Google Scholar 

  92. Ericksson L, Ahluwalia M, Spiewak J, Lee G, Sarma DSR, Roomi M, Farber E: Distinctive biochemical pattern associated with resistance to hepatocytes in hepatocyte nodules during liver carcinogenesis. Environ Health Perspect 49: 171–174, 1993

    Google Scholar 

  93. Nuwaysir E, Dragan Y, Pitot H: Tamoxifen induces hepatic cytochrome P450IIB1 and IIB2 in F344 rats. Toxicologist 12: A917, 1992

    Google Scholar 

  94. White INH, Davies A, Smith LL, Dawson S, de Matteis F: Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the liver of female rats and mice. Biochem Pharmacol 45: 21–30, 1993

    Google Scholar 

  95. Jones CR, Lubett RA: Induction of a pleiotropic response by phenobarbital and related compounds. Response in various inbred strains of rat, response in various species, and the induction of aldehyde dehydrogenase in Copenhagen rats. Biochem Pharmacol 44: 1651–1660, 1992

    Google Scholar 

  96. Dannan G, Guengerich FP: Immunochemical comparison and quantitation of microsomal flavin-containing monooxygenases in various hog, mouse, rat, rabbit, dog, and human tissues. Molec Pharmacol 22: 787–794, 1982

    Google Scholar 

  97. Board of Scientific Advisors: Report of the NTP Ad Hoc Panel on chemical carcinogenesis testing and evaluation. NTP 138-149, 1984

  98. Shi Y, Yager J: Enhancement in rats by the liver tumor promoter ethinyl estradiol of a serum factor(s) which is stimulatory for hepatocyte DNA synthesis. Biochem Biophys Res Commun 160: 154–161, 1989

    Google Scholar 

  99. Butta A, MacLennan, Flanders K, Sacks N, Smith I, McKinna A, Dowsett M, Wakefield L, Sporn M, Baum M, Coletta A: Induction of TGFβ in human breast cancerin vivo following tamoxifen treatment. Cancer Res 52: 4261–4264, 1992

    Google Scholar 

  100. Huynh H, Tetenes E, Wallace L, Pollak M:In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53: 1727–1730, 1993

    Google Scholar 

  101. Koch K, Lu X, Brenner D, Fey G, Martinez-Conde A, Leffert H: Mitogens and hepatocyte growth controlin vivo andin vitro. In Vitro Cell Develop 26: 1011–1023, 1990

    Google Scholar 

  102. Bruning P, Bonfer J, Hart A, Jong-Bakker M, Linders D, van Loon J, Nooyen W: Tamoxifen, serum lipoproteins, and cardiovascular risk. Br J Cancer 58: 497–499, 1988

    Google Scholar 

  103. Weiss D, Gurpide E: Nongenomic effects of estrogens and antiestrogens. J Steroid Biochem 31: 671–676, 1988

    Google Scholar 

  104. Osborne C, Boldt D, Clark G, Trent J: Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 4837–4844, 1983

    Google Scholar 

  105. Francavilla A, Polimeno L, Dileo A, Barone M, Ove P, Coetzee M, Eagon P, Makowka L, Ambrosino G, Mazzaferro V, Starzl T: The effect of estrogen and tamoxifen on hepatocyte proliferationin vivo andin vitro. Hepatology 9: 614–620, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dragan, Y.P., Fahey, S., Street, K. et al. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Tr 31, 11–25 (1994). https://doi.org/10.1007/BF00689673

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689673

Key words

Navigation